▶ LIRAGLUTIDE · SUBTOPIC · SAFETY PROFILE

LIRAGLUTIDE Safety Profile

For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of LIRAGLUTIDE.

OBSERVED ADVERSE EVENTS IN LITERATURE

The following adverse events have been observed in trials or animal studies of LIRAGLUTIDE. Severity, frequency, and attribution depend on the source publication.

Nausea
Vomiting
Diarrhea
Constipation
Headache
Injection-site reactions
Boxed warning for thyroid C-cell tumors

DRUG INTERACTIONS

The following interactions are reported in or theorised from the published mechanism for LIRAGLUTIDE.

Oral contraceptives (delayed gastric emptying)
Insulin / sulfonylureas (hypoglycemia risk)

CONTRAINDICATIONS REPORTED IN LITERATURE

Contraindications recorded for LIRAGLUTIDE in the published record:

Personal/family history of medullary thyroid carcinoma
Multiple endocrine neoplasia type 2

FDA REGULATORY STATUS

Approved as Victoza (T2D, 2010) and Saxenda (chronic weight management, 2014). Patent expired 2024; generic versions launched 2024-2025.

WADA REGULATORY STATUS

Not currently listed on the WADA Prohibited List (2026).

SAFETY Q+A FROM LITERATURE

▶ What's the difference between Victoza and Saxenda?

Same molecule. Victoza is FDA-approved for type 2 diabetes (2010) at maximum 1.8 mg/day. Saxenda is the same compound at higher dose (3.0 mg/day) for chronic weight management (2014).

▶ Is liraglutide WADA-prohibited?

Liraglutide is not currently listed on the WADA Prohibited List as of 2026.

▶ How is liraglutide dosed?

Per FDA labels: Victoza titrates 0.6 to 1.8 mg once daily for T2D. Saxenda titrates 0.6 to 3.0 mg once daily for weight management. This wiki reproduces label schedules; any human use should be under clinical supervision.

CITED LITERATURE

The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.

Pi-Sunyer X, Astrup A, Fujioka K, et al.. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med 2015. PMID 26132939. link
Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med 2016. PMID 27295427. link

◀ LIRAGLUTIDE OVERVIEW MECHANISM ▶DOSING LITERATURE ▶

▶ LAST UPDATED · 2026-05-25